351 related articles for article (PubMed ID: 8054280)
1. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy.
Vesalainen S; Nordling S; Lipponen P; Talja M; Syrjänen K
Br J Cancer; 1994 Aug; 70(2):309-14. PubMed ID: 8054280
[TBL] [Abstract][Full Text] [Related]
2. DNA ploidy, S phase fraction and G2 fraction as prognostic determinants in prostatic adenocarcinoma.
Eskelinen M; Lipponen P; Majapuro R; Syrjänen K; Nordling S
Eur Urol; 1991; 20(1):62-6. PubMed ID: 1743234
[TBL] [Abstract][Full Text] [Related]
3. Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis.
Bratt O; Anderson H; Bak-Jensen E; Baldetorp B; Lundgren R
Urology; 1996 Feb; 47(2):218-24. PubMed ID: 8607238
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy.
Visakorpi T; Kallioniemi OP; Paronen IY; Isola JJ; Heikkinen AI; Koivula TA
Br J Cancer; 1991 Sep; 64(3):578-82. PubMed ID: 1911201
[TBL] [Abstract][Full Text] [Related]
5. S-phase fraction related to prognosis in localised prostate cancer. No specific significance of chromosome 7 gain or deletion of 7q31.1.
Aström L; Weimarck A; Aldenborg F; Delle U; Hanson C; Verbiene I; Danielsson A; Hammarsten J; Köpf I
Int J Cancer; 1998 Dec; 79(6):553-9. PubMed ID: 9842961
[TBL] [Abstract][Full Text] [Related]
6. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.
Ahlgren G; Lindholm K; Falkmer U; Abrahamsson PA
Urology; 1997 Sep; 50(3):379-84. PubMed ID: 9301701
[TBL] [Abstract][Full Text] [Related]
7. Factors that influence the measurement of prostate cancer DNA ploidy and proliferation in paraffin embedded tissue evaluated by flow cytometry.
So MJ; Cheville JC; Katzmann JA; Riehle DL; Lohse CM; Pankratz VS; Sebo TJ
Mod Pathol; 2001 Sep; 14(9):906-12. PubMed ID: 11557788
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma.
Victorzon M; Roberts PJ; Haglund C; von Boguslawsky K; Nordling S
Oncology; 1996; 53(3):182-91. PubMed ID: 8643219
[TBL] [Abstract][Full Text] [Related]
9. Does DNA flow cytometry give useful prognostic information in renal parenchymal adenocarcinoma?
Masters JR; Camplejohn RS; Parkinson MC; Woodhouse CR; O'Reilly SM
Br J Urol; 1992 Oct; 70(4):364-9. PubMed ID: 1450842
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of DNA ploidy and nuclear morphometry in metastatic prostate cancer].
Martínez Jabaloyas JM; Jiménez Sánchez A; Ruiz Cerdá JL; Sanz Chinesta S; Sempere A; Jiménez Cruz JF
Actas Urol Esp; 2004 Apr; 28(4):298-307. PubMed ID: 15248401
[TBL] [Abstract][Full Text] [Related]
11. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
[TBL] [Abstract][Full Text] [Related]
12. Markers of prognosis in breast cancer--the relationship between binding of the lectin HPA and histological grade, SPF, and ploidy.
Brooks SA; Leathem AJ; Camplejohn RS; Gregory W
Breast Cancer Res Treat; 1993; 25(3):247-56. PubMed ID: 8369526
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric DNA analysis of stage D2 prostatic carcinoma.
Yokogi H; Mizutani M; Ishibe T
Urol Int; 1991; 47(2):57-9. PubMed ID: 1792707
[TBL] [Abstract][Full Text] [Related]
14. Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer.
Stanton PD; Cooke TG; Oakes SJ; Winstanley J; Holt S; George WD; Murray GD
Br J Cancer; 1992 Nov; 66(5):925-9. PubMed ID: 1419638
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of DNA ploidy in prostatic cancer].
Martínez Jabaloyas JM; Ruiz Cerdá JL; Sanz Chinesta S; Jiménez A; Hernández M; Jiménez Cruz JF
Actas Urol Esp; 2001 Apr; 25(4):283-90. PubMed ID: 11455830
[TBL] [Abstract][Full Text] [Related]
16. DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications.
Tinari N; Natoli C; Angelucci D; Tenaglia R; Fiorentino B; Di Stefano P; Amatetti C; Zezza A; Nicolai M; Iacobelli S
Cancer; 1993 Feb; 71(4):1289-96. PubMed ID: 8435806
[TBL] [Abstract][Full Text] [Related]
17. Biochemical parameters as prognostic factors in prostatic adenocarcinoma.
Vesalainen S; Lipponen P; Talja M; Syrjänen K
Acta Oncol; 1995; 34(1):53-9. PubMed ID: 7865237
[TBL] [Abstract][Full Text] [Related]
18. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.
Pinto AE; André S; Soares J
J Clin Pathol; 1999 Aug; 52(8):604-11. PubMed ID: 10645231
[TBL] [Abstract][Full Text] [Related]
19. A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour.
Lipponen P; Vesalainen S; Kasurinen J; Ala-Opas M; Syrjänen K
Anticancer Res; 1996; 16(4A):2095-100. PubMed ID: 8712749
[TBL] [Abstract][Full Text] [Related]
20. Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology.
Vesalainen S; Lipponen P; Nordling S; Talja M; Syrjänen K
Anticancer Res; 1995; 15(2):569-73. PubMed ID: 7763039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
